NCT03375242Completed
Safety and Efficacy of Xalkori ROS1
XALKORI ROS1+NSCLC DRUG USE INVESTIGATION
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 97 (actual)
- First submitted
- 12 Dec 2017
- Start date
- 25 Oct 2017
- Primary completion date
- 10 Aug 2026
- Lead sponsor
- Pfizer
- Diseases
- Lung cancer
- NCT number
- NCT03375242
What you commit to
- Study type: Observational
- Participants enrolled: 97
- From 25 Oct 2017 to the primary completion date, 10 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with past history of hypersensitivity to any of the ingredients of XALKORI
Who the study is looking for
- patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.